Diffusion magnetic resonance in cervical carcinoma: the role of apparent diffusion coefficient in the evaluation of treatment response

Purpose: The aim of the study was to determinate the role of apparent diffusion coefficient (ADC) in order to find cut-off values in the evaluation of treatment response. Materials and Methods: A retrospective study was undertaken on MRIs of three groups of patients: 17 with histologically proven cervical carcinoma (group 1), 16 with complete regression after chemo-radiotherapy (group 2), and 46 without pathology (group 3). Three non-overlapping ROIs were manually drawn through neoplastic tissue and normal cervical areas,. regions of interest (ROIs) median values were calculated. Student t-test, ANOVA test, receiver operating characteristic (ROC) curves, and Youden Index were performed. Results: The most important data was obtained by ROC curve and Youden index calculated between free from disease merged group (groups 2+3) and ill patients (group 1): 1.18 x10 ^-3mm ²/s (94% sensibility, 100% specificity), was the cut-off ADC value. Values below this cut-off could be considered as recurrent pathology with high accuracy. Conclusions: ADC represents a fundamental quantitative tool in follow-up of chemo-radiant treatment response in advanced cervical carcinoma.

ADC mapping; Chemoradiation; Diffusion weighted magnetic resonance; Quantitative study; Residual cervical carcinoma

[1] Jemal A., Siegel R., Xu J., Ward E.: “Cancer statistics, 2010”. CA Cancer J. Clin., 2010, 60, 277.

[2] Kesic V., Rodolakis A., Denschlag D., Schneider A., Morice P., Amant F., Reed N.: “Fertility preserving management in gynecologic cancer patients: the need for centralization”. Int. J. Gynecol. Cancer, 2010, 20, 1613e9.

[3] Pecorelli S., Zigliani L., Odicino F.: “Revised FIGO staging for carcinoma of the cervix”. Int. J. Gynaecol. Obstet., 2009, 105, 107.

[4] Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A.: “Cervix uteri”. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, 395.

[5] Balleyquier C., Sala E., Da Cunha T., Bergman A., Brkljacic B., Danza F., et al.: “Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology”. Eur. Radiol., 2011, 21, 1102.

[6] Querleu D., Morrow C.P.: “Classification of radical hysterectomy”. Lancet. Oncol., 2008, 9, 297.

[7] Denny L., Hacker N.F., Gori J., Jones H.W. III, Ngan H.Y.S., Pecorelli S.: FIGO Committee on Gynecologic Oncology. Staging Classifications and Clinical Practice. Guidelines for Gynaecologic Cancers. Available at: http://www.figo.org/publications/ staging_ classifications

[8] Thomeer M.G., Gerestein C., Spronk S., Van Doorn H.C., Van der Ham E., Hunink M.G.: “Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: Systematic review and meta-analysis”. Eur. Radiol., 2013, 23, 2005.

[9] Dhoot N.M., Kumar V., Shinagare A., Kataki A.C., Barmon D., Bhuyan U.: “Evaluation of carcinoma cervix using magnetic resonance imaging: correlation with clinical FIGO staging and impact on management”. J. Med. Imaging Radiat. Oncol., 2012, 56, 58.

[10] Stenstedt K., Hellstrom A.C., Fridsten S., Blomqvist L.: “Impact of MRI in the management and staging of cancer of the uterine cervix”. Acta Oncol., 2011, 50, 420.

[11] Le Bihan D.: “Apparent diffusion coefficient and beyond: what diffusion MRimaging can tell us about tissue structure”. Radiology, 2013, 268, 318.

[12] Naganawa S., Sato C., Kumada H., Ishigaki T., Miura S., Takizawa O.: “Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix”. Eur. Radiol., 2005, 15, 71.

[13] Kuang F., Ren J., Zhong Q., Liyuan F., Huan Y., Chen Z.: “The value of apparent diffusion coefficient in the assessment of cervical cancer”. Eur. Radiol., 2013, 23, 1050.

[14] Kilickesmez O., Bayramoglu S., Inci E., Cimilli T., Kayhan A.: “Quantitative diffusion-weighted magnetic resonance imaging of normal and diseased uterine zones”. Acta Radiol., 2009, 50, 340.

[15] Dhoot N.M., Kumar V., Shinagare A., Kataki A.C., Barmon D., Bhuyan U.: “Evaluation of carcinoma cervix using magnetic resonance imaging: Correlation with clinical FIGO staging and impact on management”. J. Med. Imaging Radiat. Oncol., 2012, 56, 5 .

[16] Padhani A.R., Liu G., Koh D.M., Chenevert T.L., Thoeny H.C., Takahara T., et al.: “Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations”. Neoplasia, 2009, 11, 102.

[17] Whittaker C.S., Coady A., Culver L., Rustin G., Padwick M., Padhani A.R.: “Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review”. Radiographics, 2009, 29, 759.

[18] Hameeduddin A., Sahdev A.: “Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies”. Cancer Imaging, 2015, 15, 3.

[19] Schreuder, M.D., Lensing R., Stoker J., Bipat S.: “Monitoring Treatment Response in Patients Undergoing Chemoradiotherapy for Locally Advanced Uterine Cervical Cancer by Additional Diffusion-Weighted Imaging: A Systematic Review”. J. Magn. Reson. Imaging, 2015, 42, 572.

[20] Okamoto Y., Tanaka Y.O., Nishida M., Tsunoda H., Yoshikawa H., Itai Y.: “MR imaging of the uterine cervix: imaging-pathologic correlation”. Radiographics, 2003, 23, 425.

[21] Charles-Edwards E.M., Messiou C., Morgan V.A., De Silva S.S., McWhinney N.A., Katesmark M., et al.: “Diffusion-weighted imaging in cervical cancer with an endovaginal technique: potential value for improving tumor detection in stage Ia and Ib1 disease”. Radiology, 2008, 249, 541.

[22] Xue H.D., Li S., Sun F., Sun H.Y., Jin Z.Y., Yanq J.X., Yu M.: “Clinical application of body diffusion weighted MR imaging in the diagnosis and preoperative N staging of cervical cancer”. Chinese Medical Sciences Journal, 2008, 23, 133.

[23] McVeigh P.Z., Syed A.M., Milosevic M., Fyles A., Haider M.A.: “Diffusion-weighted MRI in cervical cancer”. Eur. Radiol., 2008, 18, 1058.

[24] Chen J., Zhang Y., Liang B., Yang Z.: “The utility of diffusion-weighted MR imaging in cervical cancer”. Eur. J. Radiol., 2010, 74, e101.

[25] Ho K.C., Lin G., Wang J.J., Lai C.H., Chanq C.J., Yen T.C.: “Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer”. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 200.

[26] Harry V.N., Semple S.I., Gilbert F.J., Parkin D.E.: “Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer”. Gynecol. Oncol., 2008, 111, 213.

[27] Hoogendam J.P., Klerkx W.M., de Kort G.A., Bipat S., Zweemer R.P., Sie-Go D.M., et al.: “The influence of the b-value combination on apparent diffusion coefficient based differentiation between malignant and benign tissue in cervical cancer”. J. Magn. Reson. Imaging, 2010, 32, 376.

[28] Levy A., Caramella C., Chargari C., Medjhoul A., Rey A., Zareski E., et al.: “Accuracy of diffusion-weighted echo-planar MR imaging and ADC mapping in the evaluation of residual cervical carcinoma after radiation therapy”. Gynecol. Oncol., 2011, 123, 110.

[29] Vincens E., Balleyquier C., Rey A., Uzan C., Zareski E., Gouy S., et al.: “Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: correlation of radiologic findings with surgicopathologic results”. Cancer, 2008, 113, 2158.